GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Pro Medicus Ltd (ASX:PME) » Definitions » Research & Development

Pro Medicus (ASX:PME) Research & Development : A$0.0 Mil (TTM As of Dec. 2023)


View and export this data going back to 2000. Start your Free Trial

What is Pro Medicus Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Pro Medicus's Research & Development for the six months ended in Dec. 2023 was A$0.0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2023 was A$0.0 Mil.

Pro Medicus Research & Development Historical Data

The historical data trend for Pro Medicus's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pro Medicus Research & Development Chart

Pro Medicus Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Pro Medicus Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Pro Medicus Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pro Medicus  (ASX:PME) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Pro Medicus Research & Development Related Terms

Thank you for viewing the detailed overview of Pro Medicus's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Pro Medicus (ASX:PME) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Pro Medicus Ltd (ASX:PME) » Definitions » Research & Development
Comparable Companies
ASX:VHT ASX:CGS ASX:ONE ASX:M7T ASX:MDR ASX:ALC ASX:BMT ASX:PCK ASX:RHT ASX:IME GEHC VEEV SOLV TSE:2413 HQY RCM DOCS TXG EVH PGNY
Traded in Other Exchanges
PMCUF:USA PMC:Germany
Address
450 Swan Street, Richmond, Melbourne, VIC, AUS, 3121
Website
https://www.promed.com.au
Pro Medicus is a healthcare IT company specializing in radiology imaging software. Its main product, Visage 7, is a clinical desktop application that radiologists use to view, enhance, and manipulate images from any device and make a diagnosis. Its main customers are U.S. private academic hospitals. In fiscal 2022, Pro Medicus earned 79% of revenue in North America, 16% from Australia, and the remaining 6% in Europe.